RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- PMID: 21814200
- PMCID: PMC3328300
- DOI: 10.1038/nature10334
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Abstract
Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modifications. Cancer cells are characterized by altered epigenetic landscapes, and commonly exploit the chromatin regulatory machinery to enforce oncogenic gene expression programs. Although chromatin alterations are, in principle, reversible and often amenable to drug intervention, the promise of targeting such pathways therapeutically has been limited by an incomplete understanding of cancer-specific dependencies on epigenetic regulators. Here we describe a non-biased approach to probe epigenetic vulnerabilities in acute myeloid leukaemia (AML), an aggressive haematopoietic malignancy that is often associated with aberrant chromatin states. By screening a custom library of small hairpin RNAs (shRNAs) targeting known chromatin regulators in a genetically defined AML mouse model, we identify the protein bromodomain-containing 4 (Brd4) as being critically required for disease maintenance. Suppression of Brd4 using shRNAs or the small-molecule inhibitor JQ1 led to robust antileukaemic effects in vitro and in vivo, accompanied by terminal myeloid differentiation and elimination of leukaemia stem cells. Similar sensitivities were observed in a variety of human AML cell lines and primary patient samples, revealing that JQ1 has broad activity in diverse AML subtypes. The effects of Brd4 suppression are, at least in part, due to its role in sustaining Myc expression to promote aberrant self-renewal, which implicates JQ1 as a pharmacological means to suppress MYC in cancer. Our results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference (RNAi) screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3328300/bin/nihms-345676-f0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3328300/bin/nihms-345676-f0002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3328300/bin/nihms-345676-f0003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3328300/bin/nihms-345676-f0004.gif)
Similar articles
-
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.Oncotarget. 2012 Dec;3(12):1588-99. doi: 10.18632/oncotarget.733. Oncotarget. 2012. PMID: 23249862 Free PMC article.
-
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.Nature. 2015 Sep 24;525(7570):543-547. doi: 10.1038/nature14898. Epub 2015 Sep 14. Nature. 2015. PMID: 26367798 Free PMC article.
-
BET inhibitor resistance emerges from leukaemia stem cells.Nature. 2015 Sep 24;525(7570):538-42. doi: 10.1038/nature14888. Epub 2015 Sep 14. Nature. 2015. PMID: 26367796 Free PMC article.
-
The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia.Cold Spring Harb Symp Quant Biol. 2016;81:61-66. doi: 10.1101/sqb.2016.81.031039. Epub 2017 Feb 7. Cold Spring Harb Symp Quant Biol. 2016. PMID: 28174254 Free PMC article. Review.
-
Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.Curr Opin Genet Dev. 2024 Jun;86:102181. doi: 10.1016/j.gde.2024.102181. Epub 2024 Apr 2. Curr Opin Genet Dev. 2024. PMID: 38564841 Review.
Cited by
-
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.Blood Cancer J. 2024 Aug 19;14(1):138. doi: 10.1038/s41408-024-01117-4. Blood Cancer J. 2024. PMID: 39160158 Free PMC article.
-
Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance.J Natl Cancer Cent. 2021 Jan 16;1(1):15-22. doi: 10.1016/j.jncc.2020.12.003. eCollection 2021 Mar. J Natl Cancer Cent. 2021. PMID: 39036786 Free PMC article.
-
MYB as a Critical Transcription Factor and Potential Therapeutic Target in AML.Adv Exp Med Biol. 2024;1459:341-358. doi: 10.1007/978-3-031-62731-6_15. Adv Exp Med Biol. 2024. PMID: 39017851 Review.
-
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.J Nanobiotechnology. 2024 May 29;22(1):296. doi: 10.1186/s12951-024-02525-1. J Nanobiotechnology. 2024. PMID: 38811964 Free PMC article.
-
Temporal Single Cell Analysis of Leukemia Microenvironment Identifies Taurine-Taurine Transporter Axis as a Key Regulator of Myeloid Leukemia.bioRxiv [Preprint]. 2024 May 14:2024.05.11.593633. doi: 10.1101/2024.05.11.593633. bioRxiv. 2024. PMID: 38798540 Free PMC article. Preprint.
References
-
- Dickins RA, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genet. 2005;37:1289–1295. - PubMed
-
- Hemann MT, et al. An epi-allelicseries of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genet. 2003;33:396–400. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous